<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: The liver is the most frequent site of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), and extensive <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> often cause severe secondary <z:hpo ids='HP_0001410'>liver dysfunction</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, whether chemotherapy for metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> with severe <z:hpo ids='HP_0001410'>liver dysfunction</z:hpo> offers any clinical benefit is unclear since patients in this setting are typically excluded from clinical trials </plain></SENT>
<SENT sid="2" pm="."><plain>DISCUSSION: We report herein a case of metastatic sigmoid <z:hpo ids='HP_0003003'>colon cancer</z:hpo> with severe <z:hpo ids='HP_0001410'>liver dysfunction</z:hpo> that was successfully treated using infusional <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>, leucovorin, and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (FOLFOX) </plain></SENT>
<SENT sid="3" pm="."><plain>FOLFOX was effective and well tolerated in the present case, and subsequent addition of bevacizumab to FOLFOX after disease progression was similarly feasible </plain></SENT>
</text></document>